A new approach in the management of urothelial tumors using GM-CSF on marker lesions: an ultrastructural and immunohistochemical study on the macrophage population in bladder mucosa.
Our purpose was to investigate a new therapeutic model, GM-CSF-targeted immunomodulation on transitional cell carcinoma (TCC) marker lesions and to evaluate the immunologic response of the bladder mucosa. Eleven patients with pTa or pT1 bladder cancer were eligible for the study. All lesions were removed by transurethral resection (TUR) except for a marker lesion. All patients received 8 weekly instillations of 300 microg of GM-CSF, after which cystoscopy with bladder biopsies +/- TUR was repeated on adjacent urothelium or tumor or both. Paraffin-embedded sections were immunohistochemically stained with CD68, which labels monocytes and macrophages. The CD68+ cell population was evaluated as 1+ to 3+. Comparable specimens were routinely processed for ultrastructural analysis. Complete response was observed in 6 patients (55%), persistent tumor occurred in 4 patients (approximately 36.4%), and 1 patient (8.6%) showed recurrence. Immunohistochemically, an at least twofold increase in the number of the CD68+ cells was observed in all responders. Submicroscopically, migration of macrophages to the surface layer occurred. Macrophages showed an extensive lysosomal system and pseudopodia. This study indicates that the prophylactic treatment of TCC with GM-CSF may induce immunomodulatory effects on macrophage activities, which could be associated with the clinical evolution of the disease.
Stravoravdi
P
P
Theagenio Cancer Hospital, Electron Microscopy Department, Thessaloniki, Greece. natsis@med.auth.gr
Toliou
T
T
Kirtsis
P
P
Natsis
K
K
Konstandinidis
E
E
Barich
A
A
Gigis
P
P
Dimitriadis
K
K
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000368:Aged; D014408:Biomarkers, Tumor; D002295:Carcinoma, Transitional Cell / Q000737:chemistry / Q000473:pathology / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D007150:Immunohistochemistry; D008264:Macrophages / Q000737:chemistry / Q000187:drug effects* / Q000473:pathology; D008854:Microscopy, Electron; D008875:Middle Aged; D001749:Urinary Bladder Neoplasms / Q000737:chemistry / Q000473:pathology / Q000628:therapy*; D019459:Urothelium / Q000737:chemistry / Q000187:drug effects / Q000473:pathology
D000276:Adjuvants, Immunologic; D014408:Biomarkers, Tumor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor